EMD Serono Newsroom

To keep up with the latest news in real-time, subscribe to our email alerts, and follow us on Twitter, Facebook and LinkedIn. If you are a reporter and have questions about the company, please contact us

Latest News

 

Apr 8, 2019

EMD Serono, Inc. today announced that Express Scripts is covering on its formulary the oral multiple sclerosis (MS) therapy, MAVENCLAD® (cladribine) tablets, which was approved by the U.S. Food...

Mar 29, 2019

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved MAVENCLAD®...

Feb 28, 2019

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, will present data at the fourth annual ACTRIMS (Americas Committee for Treatment and Research...

Feb 16, 2019

Not intended for UK-based media JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression US FDA has...

  All Press Releases